WHO Global Market Study on RSV Immunization Products
世界卫生组织·2024-12-20 01:40
Contents a. Gestational age window is variable depending on local NRA decisions (e.g. 32-36 weeks in the US and Argentina, 24-36 weeks in Europe and Japan, 28-36 weeks in the UK) b. The registration of RSV vaccines and mAbs is rapidly evolving and presented information are based on publicly available information as of early March 2024 c. Indication for 50–59-year-old adults is only in certain countries Financial support from Gavi, the Vaccine Alliance (Gavi), for Gavi-eligible countries for RSV immunization ...